Dave Knapp

big pharmaceutical companies would want you to believe that all non-branded are created equal they're just not right so 503 b's are subject to the current goods and manufacturing process long way of saying they have fda oversight when you move to 503 a's and that's kind of what we explained earlier where you take the active ingredient and then you you do it in a dose that isn't available commercially or you add b12 because somebody has

big pharmaceutical companies would want you to believe that all non-branded are created equal they're just not right so 503 b's are subject to the current goods and manufacturing process long way of saying they have fda oversight when you move to 503 a's and that's kind of what we explained earlier where you take the active ingredient and then you you do it in a dose that isn't available commercially or you add b12 because somebody has

fatigue or whatever it may be. Niacinamide is another one that gets added a lot. So basically, there's something that's not commercially available because there's a medical need precipitating it. I think, A, they're sort of operating outside of the spirit of why 503As exist, right? Because all of a sudden, they're going to move

fatigue or whatever it may be. Niacinamide is another one that gets added a lot. So basically, there's something that's not commercially available because there's a medical need precipitating it. I think, A, they're sort of operating outside of the spirit of why 503As exist, right? Because all of a sudden, they're going to move

fatigue or whatever it may be. Niacinamide is another one that gets added a lot. So basically, there's something that's not commercially available because there's a medical need precipitating it. I think, A, they're sort of operating outside of the spirit of why 503As exist, right? Because all of a sudden, they're going to move

millions of people who are on normal dosages, just exact copies of the branded medication to these custom formulations, prescribers are going to run into problems with the FDA, I believe.

millions of people who are on normal dosages, just exact copies of the branded medication to these custom formulations, prescribers are going to run into problems with the FDA, I believe.

millions of people who are on normal dosages, just exact copies of the branded medication to these custom formulations, prescribers are going to run into problems with the FDA, I believe.

I think both will be on the receiving end of something. I think prescribers, potentially, I think the industry is preparing itself for the FDA

I think both will be on the receiving end of something. I think prescribers, potentially, I think the industry is preparing itself for the FDA

I think both will be on the receiving end of something. I think prescribers, potentially, I think the industry is preparing itself for the FDA

to come and and sort of stick their nose into the way these are being prescribed but we definitely know that both novo and lily are putting out cease and desist letters to compound pharmacies to providers to telehealth companies everybody's getting them and so once this march 19th is the cutoff that's just coming right around the corner um march 19th hits

to come and and sort of stick their nose into the way these are being prescribed but we definitely know that both novo and lily are putting out cease and desist letters to compound pharmacies to providers to telehealth companies everybody's getting them and so once this march 19th is the cutoff that's just coming right around the corner um march 19th hits

to come and and sort of stick their nose into the way these are being prescribed but we definitely know that both novo and lily are putting out cease and desist letters to compound pharmacies to providers to telehealth companies everybody's getting them and so once this march 19th is the cutoff that's just coming right around the corner um march 19th hits

That has to end, and then you'll see massive movement legally from Lilly. Novo Nordisk is like a month behind, and so semaglutide will be about a month behind that. All the telehealths are saying we're moving to custom formulations. It remains to be seen how they will respond in the face of legal threats and the legions of...

That has to end, and then you'll see massive movement legally from Lilly. Novo Nordisk is like a month behind, and so semaglutide will be about a month behind that. All the telehealths are saying we're moving to custom formulations. It remains to be seen how they will respond in the face of legal threats and the legions of...

That has to end, and then you'll see massive movement legally from Lilly. Novo Nordisk is like a month behind, and so semaglutide will be about a month behind that. All the telehealths are saying we're moving to custom formulations. It remains to be seen how they will respond in the face of legal threats and the legions of...

you know, attorneys and lawyers that will be dispatched to basically squash anything that is not the branded version, not to mention the FDA. What remains to be seen too is like how much, what's the appetite of this administration moving to enforce anything against these compounders that we don't know, but we do know that, you know,

you know, attorneys and lawyers that will be dispatched to basically squash anything that is not the branded version, not to mention the FDA. What remains to be seen too is like how much, what's the appetite of this administration moving to enforce anything against these compounders that we don't know, but we do know that, you know,

you know, attorneys and lawyers that will be dispatched to basically squash anything that is not the branded version, not to mention the FDA. What remains to be seen too is like how much, what's the appetite of this administration moving to enforce anything against these compounders that we don't know, but we do know that, you know,